阿戈美拉汀联合艾司西酞普兰治疗抑郁症伴睡眠障碍的临床疗效及安全性  

Clinical efficacy and safety of agomelatine combined with escitalopram in the treatment of depression with sleep disorder

作　　者：朱冬冬 陈进 左晓伟 杜亚运 王成东 ZHU Dongdong;CHEN Jin;ZUO Xiaowei(Xuzhou Eastern Peoplers Hospital,Jiangsu Province,Xuzhou 221000,China)

机构地区：[1]江苏省徐州市东方人民医院,221000

出　　处：《临床合理用药杂志》2021年第22期17-19,22,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察阿戈美拉汀联合艾司西酞普兰片治疗抑郁症伴睡眠障碍的临床疗效及安全性。方法回顾性选取2018年1月-2019年12月江苏省徐州市东方人民医院门诊及住院部收治的抑郁症伴睡眠障碍患者100例,根据治疗方法不同分为试验组52例和对照组48例。对照组患者使用艾司西酞普兰治疗,试验组在对照组的基础上加用阿戈美拉汀治疗。比较2组患者临床疗效;2组患者于治疗前及治疗2、4、6、8周后使用汉密尔顿抑郁量表-17(HAMD-17)评估患者抑郁症状,使用匹兹堡睡眠质量指数量表(PSQI)评估患者睡眠质量;使用不良反应量表(TESS)评估患者不良反应。结果经过8周药物治疗后,2组患者总有效率比较差异均无统计学意义(P>0.05),试验组患者痊愈率为34.62%,高于对照组的14.58%,差异有统计学意义(P<0.05)。治疗2、4、6、8周后,试验组患者HAMD-17评分、PSQI评分均低于对照组,差异有统计学意义(P均<0.01)。试验组患者不良反应总发生率为25.00%,对照组患者不良反应总发生率为18.75%,2组患者不良反应总发生率比较差异无统计学意义(x^(2)=0.588,P=0.451)。结论阿戈美拉汀联合艾司西酞普兰可有效改善抑郁症伴睡眠障碍患者睡眠障碍及抑郁症状,且安全性较高。Objective To observe the clinical efficacy and safety of agomelatine combined with escitalopram in the treatment of depression with sleep disorder. Methods A total of 100 patients with depression and sleep disorder admitted to the outpatient department and inpatient department of Xuzhou Eastern People’ s Hospital,Jiangsu Province from January2018 to December 2019 were retrospectively selected. According to different treatment methods,they were divided into experimental group( n = 52) and control group( n = 48). Control group was treated with escitalopram,and experimental group was additively treated with agomelatine. The clinical efficacy of the two groups was compared;Before treatment and 2,4,6 and 8 weeks after treatment,the Hamilton Depression Scale-17( HAMD-17) was used to evaluate the depressive symptoms of patients in the 2 groups,and the Pittsburgh Sleep Quality Index( PSQI) was used to evaluate the sleep quality of patients;Adverse reactions were assessed using TESS. Results After 8 weeks of drug treatment,there was no statistically significant difference in the total effective rate between 2 groups( P > 0. 05),the cure rate of experimental group was 34. 62%,which was higher than that of control group( 14. 58%),the difference was statistically significant( P < 0. 05). After 2,4,6 and 8 weeks of treatment,HAMD-17 and PSQI scores in experimental groups were lower than those in control group,the difference were statistically significant( P < 0. 01). The total incidence of adverse reactions was 25. 00% in the experimental group and 18. 75% in the control group,and there was no statistical significance in the total incidence of adverse reactions between the two groups( χ2= 0. 588,P = 0. 451). Conclusion Agomelatine combined with escitalopram can effectively improve sleep disorders and depressive symptoms in patients with depression and sleep disorders,with high safety.

关 键 词：睡眠障碍 抑郁症 阿戈美拉汀 艾司西酞普兰 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R740[医药卫生—临床医学]